New insights into the pathogenesis of systemic sclerosis
Introduction
Systemic sclerosis (SSc) is characterized by skin and visceral fibrosis, and vascular abnormalities including Raynaud's phenomenon, pulmonary arterial hypertension (PAH) and renal crisis [1]. Extracellular matrix overproduction by fibroblasts is the hallmark of SSc. Collagen accumulation results from abnormal interactions among endothelial cells (EC), mononuclear cells (lymphocytes and monocytes) and fibroblasts leading to the production of fibrosis-inducing cytokines, in a setting of vascular hyperreactivity and tissue hypoxia (Fig. 1) [2]. Numerous autoantibodies have been identified in the serum of SSc patients, but their pathogenetic role(s) remains uncertain. Finally, alloreactivity, together with genetic and environmental factors could contribute to disease susceptibility.
Section snippets
Cells and cytokines involved in the pathogenesis of SSc
SSc fibroblasts are activated and overproduce extracellular matrix proteins, such as collagens I, III, V, VI and VII, tenascin, proteoglycans, fibronectin, laminin and fibrillin-1 [3]. Myofibroblasts which can differentiate from fibroblasts in the presence of thrombin are mainly responsible for increased collagen production [4]. Collagen synthesis is dependent on transforming growth factor-beta (TGF-β) a cytokine produced by fibroblasts and EC, and on connective tissue growth factor (CTGF),
Autoantibodies
Autoantibodies to cellular components are detected in most SSc patients. Three of these autoantibodies are disease-specific and mutually exclusive; anti-centromere Ab (ACA), anti-topoisomerase 1 Ab (ATA) and anti-RNA polymerase (RNAP) III Ab. Other autoantibodies have been identified in SSc patients, directed against nucleolar, cytoplasm, membrane structures, extracellular matrix components, fibroblasts and/or EC.
Microchimerism
Several studies have shown an association between the development of SSc in women sometimes after pregnancy and the detection of fetal cells in peripheral blood [36], [37]. These results led to the hypothesis that SSc may be the consequence of an allogeneic fetomaternal reaction that might be a manifestation of an intergenerational HLA incompatibility [36], [37]. However, certain normal female controls also exhibit microchimerism, and its role in SSc remains unproven, but it probably
Genetic and environmental factors
With insufficient evidence supporting an environmental cause, recent attention has focused on the role of genetic factors in the occurrence of SSc. Thus, a positive family history is the strongest risk factor yet identified for SSc [38]. Human leukocyte antigen associations exist but more closely reflect the presence of particular autoantibodies than SSc and no single major histocompatibility complex allele predisposes to SSc in all ethnic groups. The fibrillin-1 gene, that is partially
Acknowledgements
This work was supported by the Association des Sclérodermiques de France and INSERM (CReS No. 4CR08F). Y. Chanseaud was funded by the Ministère de l'Enseignement Supérieur et de la Recherche, France.
References (40)
Systemic sclerosis (scleroderma) and related disorders: clinical aspects
Baillieres Best Pract Res Clin Rheumatol
(2000)- et al.
Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway
J Biol Chem
(2001) - et al.
Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma
J Dermatol Sci
(1999) - et al.
Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression
J Dermatol Sci
(2002) - et al.
The differentiation and function of myofibroblasts is regulated by mast cell mediators
J Invest Dermatol
(2001) - et al.
Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
Chest
(1999) - et al.
Microchimerism and HLA-compatible relationships of pregnancy in scleroderma
Lancet
(1998) - et al.
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis
Am J Med
(2002) - et al.
Pathogénie de la sclérodermie: aspects immunologiques
Ann Med Int
(2002) - et al.
Regulation of connective tissue synthesis in systemic sclerosis
Int Rev Immunol
(1995)
Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis
Curr Rheumatol Rep
Deficient Smad7 expression: a putative molecular defect in scleroderma
Proc Natl Acad Sci USA
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts
Arthritis Rheum
The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts
Mol Pathol
Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis
Arthritis Rheum
Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation
Br J Dermatol
Expression of stem cell factor in the lesional skin of systemic sclerosis
Dermatology
Oligoclonal T cell expansion in the skin of patients with systemic sclerosis
J Immunol
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis
Arthritis Rheum
Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies
Eur Respir J
Cited by (135)
Loss of Protein Kinase D2 Activity Protects Against Bleomycin-Induced Dermal Fibrosis in Mice
2023, Laboratory InvestigationStudy the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters
2022, Reumatologia ClinicaCardiopulmonary exercise testing in the management of systemic sclerosis
2022, Revue de Medecine InternePatient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care
2019, Seminars in Arthritis and RheumatismCitation Excerpt :Systemic sclerosis is a rare autoimmune disease involving skin, vessels, joints and internal organs such as lungs, heart, kidneys, and the gastrointestinal tract [1].
Lung disease related to connective tissue diseases
2019, Difficult to Diagnose Rare Diffuse Lung Disease